L3VLUP
ProSign in

IDYA · JNJ in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

IDYAJNJ
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • IDYA
  • JNJ
0204060202120222023202420252026
Holders and value by quarter
QuarterIDYAJNJ
Q3 20201 holders, $15m30 holders, $26.2bn
Q4 20201 holders, $16m32 holders, $26.6bn
Q1 20213 holders, $31m31 holders, $25.3bn
Q2 20213 holders, $26m37 holders, $25.6bn
Q3 20213 holders, $37m40 holders, $24.1bn
Q4 20213 holders, $50m33 holders, $25.2bn
Q1 20221 holders, $21m35 holders, $28.2bn
Q2 20221 holders, $21m33 holders, $26.9bn
Q3 2022none listed holders, n.a.36 holders, $25.4bn
Q4 2022none listed holders, n.a.35 holders, $27.6bn
Q1 2023none listed holders, n.a.42 holders, $24.5bn
Q2 20233 holders, $60m38 holders, $25.0bn
Q3 20234 holders, $118m37 holders, $18.9bn
Q4 20235 holders, $275m31 holders, $19.0bn
Q1 202410 holders, $1.0bn32 holders, $19.7bn
Q2 20248 holders, $479m35 holders, $20.4bn
Q3 20246 holders, $309m28 holders, $22.3bn
Q4 20245 holders, $245m37 holders, $20.4bn
Q1 20253 holders, $159m32 holders, $20.5bn
Q2 20253 holders, $374m31 holders, $18.4bn
Q3 20254 holders, $458m32 holders, $23.7bn
Q4 20253 holders, $495m29 holders, $27.8bn
Q1 20262 holders, $414m34 holders, $35.6bn
Q2 20263 holders, $533m33 holders, $39.1bn
IDYA

Ideaya Biosciences Inc

Holders
3
Reported value
$495m
Buyers
14
Sellers
13

Breadth +1 among 92 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations
JNJ

Johnson & Johnson

Holders
29
Reported value
$27.8bn
Buyers
13
Sellers
26

Breadth -13 among 92 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q4 2025

Among the 30 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only IDYA (1)

Point72 Asset Management LP

Only JNJ (27)

Acadian Asset Management LLC, AllianceBernstein LP, AQR Capital Management LLC, Arrowstreet Capital LP, Brevan Howard Capital Management LP, Bridgewater Associates LP, Capital World Investors, D. E. Shaw & Co., Dodge & Cox, Element Capital Management LLC, Fidelity (FMR LLC), Freestone Grove Partners LP, GAMCO Investors Inc, Hudson Bay Capital Management LP, Invesco Ltd, Man Group PLC, Markel Group Inc, Marshall Wace LLP, MFS Investment Management, Millennium Management LLC, Neuberger Berman Group LLC, Rokos Capital Management LLP, Squarepoint Ops LLC, T. Rowe Price Associates Inc, Two Sigma Advisers LP, and 2 more

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →